Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany
{{output}}
Background: The fully human monoclonal antibody guselkumab is an effective treatment option for patients with moderate to severe psoriasis. Objective: ... ...
